Results 31 to 40 of about 14,372 (211)

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Cells, 2022
Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study
Gaurav Kumar, Jacqueline Cottalorda-Dufayard, Rodolphe Garraffo, Francine De Salvador-Guillouët, Eric Cua, Pierre-Marie Roger   +5 more
doaj   +1 more source

HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.

Journal of Pharmaceutical and Biomedical Analysis, 2020
Therapeutic drug monitoring (TDM) is essential in the optimization of antiretroviral (ARV) treatments. In this work, we describe a new method for the simultaneous quantification of six molecules: the three novel ARV agents dolutegravir (DTG ...
Yi Zheng, R. Aboura, S. Boujaafar, G. Lui, D. Hirt, N. Bouazza, F. Foissac, J. Treluyer, S. Benaboud, I. Gana   +9 more
semanticscholar   +1 more source

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

The Pediatric Infectious Disease Journal, 2021
We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and
Tom G. Jacobs, K. V. van Aerde, A. Colbers, D. Burger   +3 more
semanticscholar   +1 more source

Prediction of maternal and fetal pharmacokinetics of dolutegravir and raltegravir using physiologically-based pharmacokinetic modeling

Clinical Pharmacokinetics, 2020
Background Predicting drug pharmacokinetics in pregnant women including placental drug transfer remains challenging. This study aimed to develop and evaluate maternal–fetal physiologically based pharmacokinetic models for two antiretroviral drugs ...
Xiaomei Liu, J. Momper, N. Rakhmanina, D. Green, G. Burckart, T. Cressey, M. Mirochnick, B. Best, J. V. van den Anker, A. Dallmann   +9 more
semanticscholar   +1 more source

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110)

Journal of Acquired Immune Deficiency Syndromes, 2020
Background Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor (INSTI) available in a granule formulation suitable for use in neonates and ...
D. Clarke, E. Acosta, M. Cababasay, Jiajia Wang, A. Chain, H. Teppler, S. Popson, Bobbie L. Graham, Betsy Smith, Rohan Hazra, Katherine Calabrese, Y. Bryson, S. Spector, J. Lommerse, M. Mirochnick   +14 more
semanticscholar   +1 more source

Characteristics and management of low-level viraemia in people living with HIV in a resource-limited setting: A multicentre retrospective study in Greece. [PDF]

HIV Med
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Leonidou L, Lourida G, Protopapas K, Moschopoulos CD, Zoulas D, Totsikas C, Basoulis D, Mastrogianni E, Beloukas A, Lagadinou M, Marangos M, Papastamopoulos V, Papadopoulos A, Psichogiou M.   +13 more
europepmc   +2 more sources

Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: a role for the integrated stress response

Glia, 2020
Regardless of adherence to combined antiretroviral therapy, white matter and myelin pathologies persist in patients with HIV‐associated neurocognitive disorders, a spectrum of cognitive, motor, and behavioral impairments.
Lindsay M. Roth, B. Zidane, L. Festa, Raj Putatunda, Micah A. Romer, H. Monnerie, K. Jordan-Sciutto, J. Grinspan   +7 more
semanticscholar   +1 more source

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CPT: Pharmacometrics & Systems Pharmacology, 2019
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite
Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain   +10 more
doaj   +1 more source

Physiologically-based pharmacokinetic modelling of uridine 5'-diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women. [PDF]

Br J Clin Pharmacol
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
Saffaf W, van der Velde Y, Malik PRV, Prins JR, Gordijn SJ, Touw DJ, Mian P.   +6 more
europepmc   +2 more sources

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

Nephrology, Dialysis and Transplantation, 2020
BACKGROUND Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir.
E. Ndashimye, Mariano Avino, Abayomi S. Olabode, A. Poon, Richard Gibson, Yue Li, Adam Meadows, C. Tan, Paul S Reyes, C. Kityo, Fred Kyeyune, I. Nankya, M. Quiñones-Mateu, E. Arts   +13 more
semanticscholar   +1 more source